Drug intelligence / Profile preview

NS14

Development stage: Preclinical
Lead developer: AYUB R&D

Overview

NS14 is a botanical extract derived from the essential oil of *Nigella sativa* (black cumin), currently in preclinical development by AYUB R&D for the treatment of bladder cancer. The extract is characterized by its high content of thymoquinone, a bioactive compound known for its anti-tumor, antioxidant, and pro-apoptotic properties. In preclinical models, NS14 has demonstrated the ability to inhibit the growth of bladder cancer cells. It is also being evaluated as part of a synergistic combination therapy with AYUB15, an extract of *Boswellia sacra* (frankincense), to enhance therapeutic efficacy against urological malignancies.

Other names: Nigella sativa essential oil extract

Beyond the preview

Go deeper on NS14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NS14.

Explore the full profile